Conolidine’s analgesic results stem from its conversation with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors within the central anxious technique, conolidine modulates alternate molecular targets. A Science Advancements study uncovered that conolidine interacts While using the atypical chemokine receptor ACKR3